Literature DB >> 16786465

[New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].

M Hammwöhner1, A D'Alessandro, D Dobrev, P Kirchhof, A Goette.   

Abstract

The therapeutic approach to atrial fibrillation is difficult and challenging. The effect of "classical" antiarrhythmic agents is based on their inhibitory effects on various ion channels. However, therapeutic benefit of these agents is often limited. The primary goal of this article is to discuss new therapeutic approaches using non-ion channel blocking drugs in the treatment of atrial fibrillation. Some of the substances discussed in this article have been used already in the clinical practice. Others, for example gentherapeutic approaches, are still in the experimental state. In contrast to ion channel blocking agents their efficacy is based on the suppression of structural remodeling. Hence, it can be assumed that due to these effects they may also be beneficial in the primary prevention of atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786465     DOI: 10.1007/s00399-006-0513-1

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  25 in total

1.  Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation.

Authors:  M J Mihm; F Yu; C A Carnes; P J Reiser; P M McCarthy; D R Van Wagoner; J A Bauer
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

Review 2.  New ideas about atrial fibrillation 50 years on.

Authors:  Stanley Nattel
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

3.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.

Authors:  A Goette; T Staack; C Röcken; M Arndt; J C Geller; C Huth; S Ansorge; H U Klein; U Lendeckel
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

4.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

5.  Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke.

Authors:  Hua Cai; Zongming Li; Andreas Goette; Fernando Mera; Clegg Honeycutt; Kristian Feterik; Josiah N Wilcox; Samuel C Dudley; David G Harrison; Jonathan J Langberg
Journal:  Circulation       Date:  2002-11-26       Impact factor: 29.690

6.  Angiotensin II-forming pathways in normal and failing human hearts.

Authors:  H Urata; B Healy; R W Stewart; F M Bumpus; A Husain
Journal:  Circ Res       Date:  1990-04       Impact factor: 17.367

7.  Defective cardiac ryanodine receptor regulation during atrial fibrillation.

Authors:  John A Vest; Xander H T Wehrens; Steven R Reiken; Stephan E Lehnart; Dobromir Dobrev; Parag Chandra; Peter Danilo; Ursula Ravens; Michael R Rosen; Andrew R Marks
Journal:  Circulation       Date:  2005-04-26       Impact factor: 29.690

8.  Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study.

Authors:  F N Brand; R D Abbott; W B Kannel; P A Wolf
Journal:  JAMA       Date:  1985-12-27       Impact factor: 56.272

9.  Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs.

Authors:  Akiko Shiroshita-Takeshita; Gernot Schram; Joel Lavoie; Stanley Nattel
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

10.  Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model.

Authors:  Koichiro Kumagai; Hideko Nakashima; Naoki Gondo; Keijiro Saku
Journal:  J Cardiovasc Electrophysiol       Date:  2003-08
View more
  4 in total

Review 1.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

2.  [New aspects of atrial fibrillation therapy].

Authors:  U Ravens; D Dobrev; A Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 3.  [Atrial fibrillation ablation: who comes into consideration?].

Authors:  B-D Gonska; H J Bauerle; T Japha
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-06

Review 4.  New drugs for atrial fibrillation.

Authors:  Matthias Hammwöhner; Jan Smid; Uwe Lendeckel; Andreas Goette
Journal:  J Interv Card Electrophysiol       Date:  2008-06-06       Impact factor: 1.900

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.